Floatz logo

BICALUTAMIDE

Ovarian Cancer

Gynaecologisch Oncologisch Centrum ZuidSmall moleculePhase 2/3Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
59/ 100

Competitive context

512 Active assets in the Ovarian Cancer cohort.

Asset / SponsorPhaseRating
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
TIL
Inge Marie Svane
Phase 2BB
Olaparib
Shandong University
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
Kalinski, Pawel, MD, PhD
Phase 3BB
DOXORUBICIN
Genmab
Phase 3BB

View all 50 →

Same molecule, other indications

BICALUTAMIDE is also rated in:

prostate adenocarcinomaActive
BB
Indicative · Phase 3
69 / 100
View asset →
triple-negative breast carcinomaActive
BB
Indicative · Phase 3
67 / 100
View asset →
prostate cancerActive
BB
Indicative · Phase 4
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →